Baxter (NYSE:BAX) and Satellite Healthcare said today that they inked a deal to bring Baxter’s dialysis products into Satellite’s 80-site renal care network.
Satellite, a non-profit group, is the 6th-largest dialysis and kidney disease treatment provider in the U.S. The 4-year deal will see Satellite deploy Baxter’s Amia automated peritoneal dialysis system and Revaclear dialyzer for high-flux hemodialysis. Baxter won 510(k) clearance from the FDA in October 2015 for the Amia system.
The financial details of the agreement were not disclosed.
“Baxter and Satellite Healthcare share a common goal to provide patients with a better dialysis experience,” Baxter Renal president Giuseppe Accogli said in prepared remarks. “We are pleased to continue our relationship with an organization that is clearly leading the way and revolutionizing how kidney disease patients are cared for in the U.S.”
Satellite Healthcare hopes to boost the number of patients it treats at home from 20% to 40%, according to a press release.
“Our mission is to make life better for our kidney disease patients by offering a personalized care experience that is unlike any other,” said CEO Rick Barnett. “Amia, Baxter’s new technology, is a foundational tool for Satellite Healthcare in reaching our Re-Imagine Home goal to make home dialysis an accessible and effective modality option for more dialysis patients.”
